-
May 08, 2024The clinical trial application of an siRNA drug developed by SanegeneBio and Innovent for the treatment of hypertension has been accepted by the CDEMore
-
Feb. 26, 2024SanegeneBio siRNA drug targeting C3 has been approved for Phase I clinical trial in New ZealandMore
-
Jan. 27, 2024Say hello to SanegeneBio new logoMore
-
Dec. 27, 2023SanegeneBio and Innovent Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of HypertensionMore
-
Dec. 01, 2023SanegeneBio Raised nearly $100 Million in Series A+ Financing Led by Tencent Investment and Yuanbio Venture Capital, to Advance Development of RNAi TherapeuticsMore
-
Nov. 09, 2023SanegeneBio and Huadong Medicine Collaborate to Develop Novel siRNA Drugs for the Treatment of Chronic Metabolic DiseasesMore
-
Oct. 07, 2023SanegeneBio first RNAi drug was approved for clinical trial in ChinaMore
